COLORADO SPRINGS, Colo., March 20, 2015 /PRNewswire/ -- Cannabis Science, Inc. (OTCQB: CBIS), a U.S. company specializing in cannabis formulation-based drug development and related consulting, today announced that accomplished scholar, epidemiologist, and public health physician Allen A. Herman, M.B., Ch.B., Ph.D. has joined its scientific advisory board.
Dr. Herman, while serving as a project officer and program director at the National Institutes of Health (NIH) designed the basis for a nationwide $160 million infant mortality reduction program and was the co-director of joint projects between the NIH and the Centers for Disease Control and Prevention (CDC). His work as the scientific director of a $25 million NIH Infant Mortality Reduction research program defined much of the basis for much of the current community-based maternal and child health public health work designed to provide a healthy start for families. For his work in maternal and child health Dr. Herman received the National Institutes Award of Merit. In addition to his work on maternal and child health, Dr. Herman was a member of the World Mental Health Survey team and helped design and execute the South African Stress and Health Study, the largest mental health survey in Africa.
He was the founding Dean of the Republic of South Africa's National School of Public Health. Dr. Herman also served as scientific advisor to then deputy-president (and now president) of the Republic of South Africa, Jacob Zuma and the South African Minister of Defense in the design and execution of a substantial HIV/AIDS treatment program for the South African National Defense Force. Dr. Herman and Mr. Dellums secured $100 million from Bristol-Myers Squibb. These funds were used to develop the 'Secure the Future' project, a research and scientific development program in southern Africa. Dr. Herman served as a Principal Investigator and on the Scientific Advisory Board of 'Secure the Future'.
Dr. Herman was also the Advisor to Ronald V. Dellums, who served President Bill Clinton as the Chairman of the U.S. Presidential Committee on HIV/AIDS. In this capacity, Dr. Herman, Mr. Dellums and Congresswoman Barbara Lee (the founding co-chair of the Congressional HIV/AIDS Caucus) developed the successful congressional legislation for the "AIDS Marshall Plan for Africa" which formed the basis of the President's Emergency Plan for AIDS Relief (PEPFAR). For his work in HIV/AIDS, Dr. Herman received the 'Heroes in Medicine' award from the International Association of Physicians in AIDS Care.
Dr. Herman will report directly to the President & CEO, Mr. Raymond C. Dabney to assist him in tracking and monitoring the multiple international drug development programs the company has underway. Because of Dr. Herman's expertise in international healthcare management and physician and health professional continuing education he will be key to assist Mr. Dabney on a daily basis to report to the public the Company's scientific progress and accomplishments.
"This is an exciting opportunity for me to work closely with Mr. Dabney and the CBIS Team. I look forward to assisting the team with a strong educational based tracking system focused on developing promising pharmaceutical products and delivery mechanisms that have the potential to help many patients with many critical ailments around the world," said Dr. Herman. "The promise is as huge as the need, worldwide."
"We now have yet another cornerstone that will help us take the company to the next level. Dr. Herman will join our well-respected and accomplished team of pharmaceutical drug development specialists. We are growing so fast that Dr. Herman's main duty will be to report our international activities as one, so the team is up to speed and working closely as one unit as we grow exponentially," stated, Mr. Dabney.
Please click here to review Dr. Herman's full CV:
About Cannabis Science, Inc.
Cannabis Science, Inc., takes advantage of its unique understanding of metabolic processes to provide novel treatment approaches to a number of illnesses for which current treatments and understanding remain unsatisfactory. Cannabinoids have an extensive history dating back thousands of years, and currently, there are a growing number of peer-reviewed scientific publications that document the underlying biochemical pathways that cannabinoids modulate. The Company works with leading experts in drug development, medicinal characterization, and clinical research to develop, produce, and commercialize novel therapeutic approaches for the treatment for illnesses caused by infections as well as for age-related illness. Our initial focus is on skin cancers, HIV/AIDS, and neurological conditions. The Company is proceeding with the research and development of its proprietary drugs as a part of this initial focus: CS-S/BCC-1, CS-TATI-1, and CS-NEURO-1, respectively.
This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing words such as "anticipate," "seek," intend," "believe," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc., does not undertake any duty nor does it intend to update the results of these forward-looking statements. Safe Harbor Statement. The Private Securities Litigation Reform Act of 1995 provides a 'safe harbor' for forward-looking statements. Certain of the statements contained herein, which are not historical facts are forward looking statements with respect to events, the occurrence of which involved risks and uncertainties. These forward-looking statements may be impacted, either positively or negatively, by various factors. Information concerning potential factors that could affect the company are detailed from time to time in the company's reports filed with the Securities and Exchange Commission.
VAN STONE PUBLICITY
Carrol Van Stone
Cannabis Science, Inc.
Raymond C. Dabney
President & CEO, Co-Founder
Chad S. Johnson, Esq.
Director, COO & General Counsel
SOURCE Cannabis Science, Inc.